Irinotecan Hikma

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Hikma, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats metastatic colorectal cancer and is used as adjuvant therapy for colon cancer in adult patients.

GNH USA supplies Irinotecan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan Hikma is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.

- Metastatic colorectal cancer: improves overall survival when combined with other chemotherapeutic agents. - Adjuvant treatment of colon cancer: reduces the risk of disease recurrence after surgical resection. - Colorectal cancer (advanced setting): provides disease control as part of multi‑drug regimens.

Irinotecan may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting - Diarrhea (often severe) - Neutropenia - Alopecia - Fatigue - Abdominal cramping

Serious or Rare Side Effects: - Febrile neutropenia - Severe colitis or intestinal perforation - Hepatic toxicity (elevated transaminases) - Anaphylactic or severe infusion reactions - Hemorrhagic cystitis - Severe electrolyte disturbances

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for toxicity.

- Monitor blood counts: perform regular complete blood counts to detect neutropenia. - Assess liver function: check hepatic enzymes and bilirubin prior to each cycle. - Evaluate bowel status: avoid use in patients with recent bowel obstruction or inflammatory bowel disease. - Adjust for renal impairment: consider dose modification in patients with reduced renal clearance. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir, indinavir) – can increase SN‑38 levels and toxicity. - Concurrent myelosuppressive agents – heighten risk of severe neutropenia.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin) – monitor INR for bleeding risk. - Diuretics – watch for electrolyte imbalances, especially with diarrhea. - Antacids containing aluminum or magnesium – may affect absorption of oral supportive medications.